Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MHB-036C (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Breast cancer; Carcinoma; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic ductal carcinoma; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Sweat gland disorders; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Minghui Pharmaceutical (Shanghai)

Most Recent Events

  • 20 Jun 2023 According to a Minghui Pharmaceutical (Shanghai) media release, first patient has been dosed in phase 1 clinical study and phase 1 study anticipated to conclude in 2024. Results from phase 1 study expected.
  • 20 Jun 2023 Status changed from not yet recruiting to recruiting, according to a Minghui Pharmaceutical (Shanghai) media release.
  • 05 Jan 2023 Planned initiation date changed from 10 Dec 2022 to 23 Jan 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top